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ABSTRACT 
Urgency urinary incontinence (UUI), the result of conditions such as overactive bladder (OAB), 
could potentially be influenced by both commensal and urinary tract infection-associated bacteria. 
The sensing of bladder filling involves interplay between various parts of the nervous system 
eventually resulting in contraction of the detrusor muscle during micturition. Here we model host 
responses to various urogenital bacteria, firstly by using urothelial bladder cell lines and then with 
myofibroblast contraction assays. To measure responses, we examined calcium influx, gene 
expression and alpha smooth muscle actin deposition assays. We found that organisms such as 
Escherichia coli IA2 and Gardnerella vaginalis ATCC 14018 strongly induced calcium influx and 
contraction, whereas, Lactobacillus crispatus ATCC 33820 and L. gasseri KC-1 did not induce 
this response. Additionally, supernatants from lactobacilli impeded influx and contraction induced 
by the uropathogens. Upon further investigation of factors associated with the purinergic signaling 
pathways, we found that influx and contraction of cells correlated to the amount of extracellular 
ATP produced by G. vaginalis ATCC 14018 and E. coli IA2. Certain lactobacilli appear to mitigate 
this response by utilizing extracellular ATP or producing inhibitory compounds which can act as 
a receptor agonist or calcium channel blocker. These findings suggest that members of the urinary 
microbiota may be influencing UUI.   
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1  Introduction  
1.1 Focus of thesis  
The focus of this thesis is to explore the mechanism used by Lactobacillus crispatus ATCC 
33820 and Lactobacillus gasseri KC-1 to reduce the stimulation of calcium influx and 
myofibroblast contraction caused by uropathogens. This work relates to the regulation of bladder 
contractility and reducing the severity of urgency urinary incontinence (UUI).  
 
1.2 Bladder physiology  
Bladder physiology consists of two phases: a storage phase and a voiding phase. The 
storage phase is controlled by the sympathetic nervous system, where the norepinephrine-releasing 
hypogastric nerve as an adrenergic nerve causes relaxation of smooth muscle cells in the bladder 
wall and causes contraction of the internal sphincter1. The voiding phase is controlled by the 
parasympathetic nervous system where stimulation of the pelvic nerve as a cholinergic nerve 
results in the release of acetylcholine, which in turn invokes smooth muscle contraction1. These 
responses in the bladder are to eliminate urine in regular intervals. However, physical and 
psychological disorders accompanied by other factors can disrupt the normal physiology of the 
bladder and lead to disease2.   
Beyond the cholinergic and adrenergic systems, the physiology of the bladder is controlled 
by various other neurotransmitters or neuroactive compounds which can exert different effects.  
Examples of these include adenosine triphosphate (ATP) and gamma-Aminobutyric acid (GABA), 
which have excitatory and inhibitory effects respectively. These can both be released by the 
nervous system, urothelial cells and potentially by different strains of bacteria, which all can have 
effects on bladder physiology 3-5.    
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1.3 Bladder diseases  
There are a number of diseases that can affect the bladder: cancer, overactive bladder 
(OAB) syndrome, urgency urinary incontinence (UUI: involuntary loss of urine associated with 
urgency), stress urinary incontinence (SUI: involuntary loss of urine on effort or physical exertion, 
or on sneezing or coughing), urinary tract infection (UTI), and asymptomatic bacteriuria (ABU). 
With the exception of ABU, some common symptoms and signs can be found, such as the loss of 
bladder control leading to the involuntary leakage of urine as well as an increased frequency or 
urgency to urinate. In addition, UTIs can be accompanied by suprapubic pain and fever6. In 
contrast, although the urine of a patient with ABU contains the equivalent bacterial viable count 
as someone with a UTI, no symptoms and signs are expressed1.  
 
1.3.1 Urgency urinary incontinence  
In patients that suffer from overactive bladder and UUI, the bladder feels fuller than it 
actually is.  The frequent sensation to urinate is based on the contraction of smooth muscle cells 
in the bladder wall7. Three large studies conducted in Europe and North America report prevalence 
of UUI from 1.8% to 9.3% in men and from 3.9% to 24.4% in women8, accompanied by social, 
psychological, and economical burden9,10.  
The inability to properly control micturition is associated with depression, anxiety, social 
isolation, reduced functional status, increased risk of institutionalization and overall negative 
impact on quality of life6. The economic burden of UUI in America is projected to be $82.6 billion 
by 20206. Despite the devastating impact of UUI, we still do not fully understand its underlying 
pathophysiology and this is a significant barrier to the development of targeted interventions aimed 
at eliminating or reducing symptoms5. Several subtypes of urinary incontinence (UI) have been 
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defined by the International Continence Society, including UUI, SUI and mixed UI (MUI: 
involuntary loss of urine associated with urgency and with exertion, effort, sneezing or 
coughing)10, 11. Longitudinal studies and a systematic review of OAB and UUI suggest that these 
conditions are often chronic and symptom severity increases over time for many patients12,13. 
 
1.3.2 Frequent urination in patients with bacterial vaginosis 
Bacterial vaginosis (BV) is a condition associated with bacterial dysbiosis with depletion 
of lactobacilli and overgrowth of bacteria such as Gardnerella vaginalis. This organism is 
commonly found as a component of the urinary microbiota14, likely through ascension from the 
vagina and urethra. Patients with BV often report the urgent need to urinate, and bladder 
contractions can increase after intercourse, potentially because of compounds released from G. 
vaginalis into the bladder14.   
 
1.4  Bladder microbiome  
The urinary tract above the urethra and including the bladder was long believed to be 
sterile.  But, new methods such as 16S rRNA gene sequencing and advanced quantitative urine 
culture techniques have shown that numerous bacterial types are present and alive in this organ15-
17.  
The genus Lactobacillus has been found in urine more frequently in healthy subjects 
compared to patients with UUI (60% versus 43%), while Gardnerella was more abundant in 
patients (26% versus 12% in controls)18. Interestingly, L. gasseri is considerably more prevalent 
in UUI patients than L. crispatus, raising questions about how different species adapt to the bladder 
environment18.  
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1.4.1  The protective role of commensal bacteria  
The discovery that bacteria permanently persist in the bladder may have a significant 
impact on health. Although the actual protective role of bacteria is still unknown, recent research 
has been able to find many links between dysbiosis in the urinary microbiota and bladder 
diseases19,20. Lactobacilli are facultative anaerobic bacteria that produce antimicrobial substances 
such as lactic acid which decrease the pH of the vagina, contributing to protection against certain 
pathogens21,22. They can also regulate and help maintain epithelial junctions, degrade toxic 
compounds released by pathogens, and reduce the ability of pathogens to adhere to the 
uroepithelium23.   
 
1.5 Uroepithelial barrier  
The uroepithelium creates a line of separation between bacteria and underlying muscle and 
nerve tissues of the bladder. In addition to being a simple barrier, the urothelium acts as a sensory 
network to detect mechanical and chemical changes in the bladder24. The uroepithelial cells 
express receptors for different neurotransmitters and release neurotransmitters into the sub-urethral 
space and lumen of the bladder. These neurotransmitters include ATP, nitric oxide (NO) and 
acetylcholine (Ach), which provide signals to the muscular and nervous networks to regulate 
bladder contraction25,26.  
Since the level of ATP released by urothelial cells fluctuates and as it depends on various 
bladder dysfunctions such as interstitial cystitis, OAB and painful bladder syndrome, ATP released 
into the voiding fluid can be measured as an indicator of these diseases27-30. The uroepithelial cells 
shed, particularly during UTI, and exposure of inner layers to bacteria and their by-products can 
worsen the neurological disorders31, 32. This may explain urinary frequency accompanying UTI, as 
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well as loss of bladder control, since normal sensory and motor signaling pathways can be 
disrupted33.  
 
1.5.1  Urothelial receptors and channels  
Transient receptor potential (TRP) plays a key role in nociceptive and mechano-sensory 
transduction in various organs. The bladder contains several TRP channels including TRPV1, 
TRPV2, TRPV4, TRPV8 and TRPA1 which are expressed in both urothelium and interstitial cells. 
Inflammation and injury in the urothelium can alter TRP channel expression34-36.  
The increased expression of TRPV1 indicates neuropathic pain and hyperalgesia37. In 
addition, the number of TRPV1 on nerve fibers increases in neurogenic detrusor overactivity. The 
TRPV1 channel is considered as a new therapeutic target for development of painkillers38. 
Stimulation of TRPV1 and TRPV4 can cause release of ATP and nitric oxide by the urothelium39.  
N-methyl-D-aspartate (NMDA) is an important receptor where the main subunit of this 
receptor is encoded by GRIN1. Activation of this channel requires binding of glutamate to the 
epsilon subunit and binding of glycine to the zeta subunit. This channel is highly permeable to 
calcium ions40 and it can thereby regulate the level of Ca2+ influx. In addition, NMDA can mediate 
the release of neurotransmitters through the bladder urothelium41. The activity of NMDA receptor 
in interstitial cystitis is increased42. Blocking the NMDA receptor can reduce bladder hypertrophy 
during interstitial cystitis and reduce bladder contractility43. 
The purinergic receptor 2 (P2) families contain P2X and P2Y expressed in the urothelium 
as well as in sub-urothelial afferent nerves and myofibroblasts44-47. In response to stertching48, 
ATP can be released through the urothelium. The P2 receptor agonists can stimulate the urothelium 
to produce ATP49. In addition, during the voiding phase, neuronal and non-neural (urothelial) 
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sources are forced to release Ach, which then stimulates muscarinic receptors on urothelial cell 
and smooth muscle cell, causing bladder contraction50.  
Many receptors mentioned above are expressed across various cell types including 
urothelial cells, sub-urethral tissues like myofibroblast, smooth muscle and the nervous 
tissue51,52,53.  Many receptors and ion channels are expressed in urothelial cells, which makes it 
possible to respond to different stimuli such as: Ach, ATP, noradrenaline, stretching during bladder 
filling, and even pH response54-62.  
 
1.5.2 Myofibroblast receptors and channels  
The lamina propria lies under the urothelium and constitutes a layer of interstitial cells that 
are spindle-shaped with intracellular connections to myofibroblasts, connective tissue elements 
and neighboring sub-urethral nerves51, 52,63. Many receptors involved in smooth muscle contraction 
are also expressed in the myofibroblast, such as muscarinic, purinergic and TRPV1 receptors64. 
 
1.5.3 Detrusor smooth muscle cell receptors and channels 
The detrusor muscle cells are located in the bladder wall. The detrusor muscle remains 
relaxed to allow the bladder to store urine, but it contracts to void the urine65.   
Many receptors such as muscarinic, purinergic and TRPV1 that are expressed in urothelial 
cell and sub-urethral tissue can also be expressed in smooth muscle cell.  Some bacterial 
compounds released into the lumen of the bladder can pass through a compromised urothelium 
and after crossing the sub-urethral can reach smooth muscle cells and change bladder 
contractility51, 52, 63. 
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1.5.4 Urothelial enzymes  
Monoamine oxidases are mitochondrial enzymes with high expression level in many 
organs. Enzymes such as MAOA and MAOB can degrade biogenic neuroactive chemicals, 
including dopamine, while MAOA degrades serotonin and norepinephrine, MAOB can degrade 
phenylethylamine. Reduction in the levels of these enzymes can lead to neurological disorders66, 
67. 
 
1.6 ATP and micturition  
ATP is an essential neuroactive molecule that is released in response to stretch and stimuli 
by neuronal sources such as parasympathetic nervous system and non-neuronal sources including 
the uroepithelium. It is an essential molecule for the onset of normal reflux of micturition and it 
acts on several different G-protein-coupled P2Y and ionotropic P2X receptors. The stimulation of 
P2X3 receptors causes an increase in afferent nerve activity, thereby increasing the sensation of 
bladder fullness and pain. In woman with bladder dysfunction the release of ATP is increased due 
to stretching68-73.  
In addition, ATP can increase the amount of intracellular Ca2+ by two routes: through 
purinergic and TRPV1 channels from the plasma membrane, or through the endoplasmic reticulum 
(ER)74. 
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1.6.1 The role of calcium in bladder function  
Calcium has a vital role in the release of neurotransmitters by cells. Increasing the level of 
intracellular calcium can regulate important mechanisms in the cell, including gene transcription, 
proliferation and metabolism75. In urothelial cells, many receptor types such as those associated 
with purinergic and TRP, pass calcium from outside to inside. Some of these receptors are sensitive 
to ATP and are also expressed in urothelial, sub-urethral tissues and smooth muscle cells. ATP, 
by increasing the level of intracellular calcium can lead urothelial cell to depolarization phase 
which is an excitatory phase and is essential for cell function. The depolarization phase can result 
in the release of compounds such as ATP and Ach into the sub-urethral space, which can alter the 
contractility of the bladder. In this regard, the continuous activation of these receptors, which 
causes the cytotoxic level of intracellular calcium, can force cells to mitochondrial dysfunction 
and apoptosis.  Uropathogenic bacteria can stimulate these receptors and cause the influx of 
calcium and, by driving the cells into the depolarization phase, excitatory compounds such as ATP 
can be released.76-80.  
 
1.7 The role of anion channel to balance anions and cations inside the cell  
Although excess intracellular calcium can push the cell towards apoptosis. But, the normal 
level of intracellular calcium is essential for cell function and regulates important cell 
mechanisms81. Therefore, the cell needs an inhibitory function or mechanism to control the level 
of intracellular calcium in order to balance anions and cations. 
Anionic channels, such as volume-regulated anion channels (VRACs), GABA receptors, 
and glycine receptors, play key roles in the influx and efflux of anions to balance anions and cations 
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within the cell. By increasing the level of anions like chloride inside of the cell, the voltage of the 
cell is decreased. When GABA and glycine stimulate their respective receptors, they can cause 
chloride influx and protect the cell against the side-effect of excess Ca2+, as well as leading the cell 
to hyperpolarization, an inhibitory phase82,83. Commensal bacteria in the intestine can release 
GABA and other inhibitory compounds84, though this has yet to be shown for bacteria originating 
in the urinary tract. The GABA could protect cells from compounds produced by uropathogens, 
leading to stimulation of calcium influx and depolarization. 
 
1.7.1 GABA receptor agonists (GABAergic) and bladder function  
The pudendal afferent nerve can inhibit bladder contraction and increase bladder capacity 
when stimulated by GABAergic mechanisms85. 
GABA confers noncholinergic and noradrenergic effects in the bladder that can inhibit the 
release of Ach from postganglionic cholinergic neurons through bicuculline-sensitive receptors. 
GABA may be associated with the chloride ion channel but not with the adrenergic inhibitory 
system, thereby allowing it to reduce bladder contractility86.  We know that purinergic and TRPV1 
receptors expressed in urothelial and detrusor smooth muscle cells are sensitive to ATP and 
stimulate calcium influx and smooth muscle cell contraction. Thus, GABA, as an inhibitory 
neurotransmitter, could potentially stimulate chloride channels and reduce UUI symptoms caused 
by ATP. 
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1.8 The release of neurotransmitters by bacteria  
The presence of a urinary microbiota raises the question of whether they can interact with 
the nervous system, given that the urinary tract is linked to the vagus nerve along with the gut. 
Studies have shown that the gut microbiota release neuroactive molecules such as GABA, 
serotonin, and norepinephrine, whose effects can be conveyed to the brain via the vagus nerve35, 
36, 66.  
Some of these neuroactive molecules play signaling roles in the human body and 
demonstrate activity in the bladder. These neurotransmitters may bind to host receptors on 
uroepithelial cells or afferent nerves in the bladder and cause the release of host neurotransmitters 
or initiate detrusor muscle contraction87, 88.  
As an intracellular source of energy, ATP is used by eukaryotic and prokaryotic cells. It 
has been shown that certain bacterial species can release ATP, though the rate may differ between 
strains67, 40, 89, 90.  ATP can act on both ionotropic and metabotropic receptors that then activate the 
purinergic receptor which increases intracellular Ca2+ levels91. Furthermore, ATP can induce Ca2+ 
influx through TRPV1 from the plasma membrane and stimulate Ca2+ influx through the ER92.  
Additional interactions are worthy of mention. For example, nitric oxide can induce the 
release of neurotransmitters such as GABA through Ca2+-dependent exocytotic release 
mechanisms and Na+-dependent mechanisms93. Lactobacilli and bifidobacteria can generate nitric 
oxide in the presence of nitrate and nitrite94. Glutamic acid produced by lactic acid bacteria and 
other acid-resistant bacteria can find its way into the extracellular medium. Glutamate 
decarboxylases (GAD) are involved in the production of GABA by decarboxylation of glutamate 
in the bacterial cell95, 96. 
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1.9 A proposed mechanism for the role of bacteria in inducing contraction or 
relaxation in the bladder  
Given the information discussed about the production of molecules by bacteria and the 
effect that these molecules can have on muscle contractility, a mechanism can be proposed for the 
involvement of these organisms in bladder function.  During UTI, uropathogenic bacteria could 
release neurotransmitters into the bladder lumen and, by stimulating related receptors, the 
urothelium releases its own neurotransmitters that could act on the nerves and subsequent muscles 
potentially causing involuntary bladder contraction97, 98.   
Bacteria could change bladder contractility by two methods. During UTIs, the invading 
uropathogens could stimulate uroepithelial receptors and cause calcium influx by releasing 
excitatory compounds like ATP [Fig 1]. Purinergic receptors, muscarinic receptors, and transient 
receptor potential channels are expressed in urothelial and sub-urothelial cells such as 
myofibroblasts, and smooth muscle cells and can function as calcium channels. By increasing the 
level of intracellular calcium, the voltage of the cell would increase, and this would lead to the 
depolarization phase essential for cellular function. This would drive the cell to release compounds 
in the sub-urethral space [Fig 1]. The released compounds, such as ATP and Ach by urothelial cell 
in sub-urethral space, could induce contraction of smooth muscle cells. The working hypothesis 
for this project is that bacterial compounds indirectly change bladder contractility. On the other 
hand, some of these compounds may be able to cross a compromised uroepithelium and, after 
crossing the sub-urethral space, can reach the smooth muscle cells and directly stimulate their 
receptors resulting in bladder contraction.  
13 
 
While the increase in intracellular calcium level is essential for cellular function, the 
continued activation of some receptors may result in mitochondrial dysfunction and ultimately 
lead to apoptosis.  
By releasing inhibitory compounds like GABA, indigenous bacteria may stimulate 
receptors on urothelial cells and cause chloride influx.  This could then cause an anion-cation 
equilibrium and, by decreasing intracellular voltage, lead the cell to hyperpolarization as an 
inhibitory phase. [Fig 1].   
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Figure 1: GABA can inhibit the stimulation of calcium cause by ATP.  ATP as an excitatory 
compound can play an agonistic role for purinergic receptors and TRP channels (1). The calcium 
influx causes an increase in the intracellular voltage and leads the urothelial cell to the 
depolarization phase119 (2), resulting in the release of certain excitatory compounds such as ATP 
into the suburethral space (3). Inhibitory compounds such as GABA with agonist effects on 
chloride channels can stimulate GABA receptors (4), causing the chloride influx. By decreasing 
the intracellular voltage, these receptors try to balance cation and anion levels in the cell, and by 
driving the cell to hyperpolarization (5) can control the urothelial secretion and regulate bladder 
contractility. 
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1.10 Rational for the project 
Bladder physiology is influenced beyond cholinergic and adrenergic systems, with several 
neurotransmitters and neuroactive compounds able to play stimulatory or inhibitory roles to 
influence different bladder phases63, 64. It is proposed that commensal bacteria play a major role in 
bladder homeostasis and this could have effects in patients with UTI and UUI99-101.  
By releasing compounds that have neurotransmitter activity, bacteria may induce calcium 
influx leading to contractility of smooth muscle cells, or inhibition of contractility which thereby 
allows the patient to have better control from UUI.  
 
1.10.1 Hypothesis  
It was hypothesized that ATP-releasing uropathogenic bacteria may change bladder contractility 
while some strains of Lactobacillus inhibit it by releasing neuroactive compounds or sequestering 
excitatory compounds. 
1.10.2 Objectives:  
A. Evaluate the ability of bacteria to release excitatory and inhibitory compounds that 
stimulate and inhibit calcium influx in urothelial cells.  
B. Evaluate the ability of bacterial supernatants to induce contraction in myofibroblasts 
measured by collagen gel contraction assay.  
C. Evaluate the ability of bacterial compounds in the bladder to alter uroepithelial gene 
expression.  
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Chapter 2: Methods and 
Materials 
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2 Materials and Methods  
2.1 Bacterial supernatant preparation 
Escherichia coli IA2 UPEC was maintained on Luria broth agar (LB, Difco, MD), 
Lactobacillus gasseri KC-1, Lactobacillus crispatus ATCC 33820, Enterococcus faecalis ATCC 
33186, were maintained on de Man, Rogosa and Sharpe agar (MRS, Difco, MD), Gardnerella 
vaginalis ATCC 14018, Lactobacillus vaginalis NCFB 2810 were maintained on Columbia Blood 
Agar (CBA, Difco, MD) and Gardnerella Selective Agar (Difco. MD). For these studies, all strains 
of bacteria were grown in artificial urine102 which in preliminary experiments was shown not to 
stimulate the influx of calcium when in the presence of human cell lines.  
Supernatants were collected from cultures grown overnight (24 hours) at 37°C after 
reaching stationary phase. Cultures were pelleted by centrifugation at 5000 rpm (Eppendorf 
Centrifuge 5804 R) for 15 minutes. The supernatant was pH adjusted to 7.0 with 0.1 M HCL or 
NaOH, filter sterilized with 0.22 um sterile syringe filter, and aliquoted and stored at -20 C° until 
use. In the case of E. coli IA2 and E. faecalis ATCC 33186, overnight cultures were diluted 1:100 
with fresh artificial urine, returned to incubation at 37 °C and sampled at 1, 2, 3, 4, 5 and 24 hours 
for testing. For the experiments involving the addition of supernatants from L. crispatus ATCC 
33820 or L. gasseri KC-1 to that from uropathogens, the urothelial cells were first treated with L. 
crispatus ATCC 33820 or L. gasseri KC-1 supernatant for one minute, then the uropathogenic 
supernatant was added. In the case of serial dilution, L. crispatus ATCC 33820 supernatant was 
diluted for 6-fold to the E. coli IA2 supernatant.  
For investigating the sub-therapeutic concentration of ciprofloxacin, the L. crispatus 
ATCC 33820 was grown in deMan, Rogosa, Sharpe media (MRS, Difco, MD). Growth curves for 
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these bacteria were generated using a plate reader (Eon Biotek, VT) at OD600 and 37˚C to 
determine exponential phase. 
 
2.2 Cell culture 
Bladder epithelial cells (5637 –ATCC HTB-9) were maintained in RPMI 1640 (Roswell-
Park Memorial Institute media – Thermo Fisher Scientific, MA) supplemented with 10% fetal 
bovine serum (FBS) (Thermo Fisher Scientific, Ma.) and 2 mM L-glutamine (Thermo Fisher 
Scientific, MA.) at 37˚C and 5% CO2. The media was changed every 48 hours or more regularly 
if the cells were confluent (90%-100%), after washing by 1X PBS and trypsinization by 0.25% 
Trypsin-EDTA (1X) (Gibco), with the ratio of 1 to 10.   Primary myofibroblast cells were extracted 
from the palmar fascia during surgery from normal tissue. Primary cultures were maintained in 
DMEM with 10% fetal bovine serum (FBS; Life Technologies, Carlsbad, CA, USA), 1% L-
glutamine (Life Technologies) and 1% antibiotic–antimycotic solution (Life Technologies) at 
37°C in 5% CO2. All primary cell lines were used up to a maximum of four passages, after which 
they were discarded. 
 
2.3 RNA isolation and qPCR from cell lines 
RNA was isolated from the samples (200 ng/μL) using the Ambion by Life Technologies 
Purelink™ RNA mini kit (Thermo Fisher Scientific, MA), following the manufacturer’s 
instructions. cDNA was made following the instructions on the Applied Biosystems High Capacity 
cDNA Reverse Transcription Kit (Thermo-Fisher Scientific, MA) and PCR was conducted using 
a Master Cycler gradient PCR thermal cycler (Eppendorf, NY). Using GAPDH as the 
housekeeping gene, qPCR was set up with each sample being run on the plate in triplicate for each 
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of the conditions. A list of the primer sequences used can be found in Table 1. Power SYBR Green 
PCR Master Mix was used (Thermo Fisher Scientific, MA). 
 
2.4 Intracellular calcium influx measured by fluorescent microscopy  
The influx of calcium was measured using the Fluo-4 DirectTM Calcium Assay kit 
(InvitrogenTM, CA). Samples and reagents were prepared according to the protocol manual 
provided. Ninety-six well plates were seeded with 100 µl of 5637 cells at 1x105 cells/mL in 
supplemented RPMI and allowed to reach confluency, which occurred at about 48-72 hours. Cells 
were counted by using the Invitrogen Countess Automated Cell Counter (Thermo Fisher Scientific, 
MA.) per the manufacturers’ instructions. Fifty microliters of cell culture media were removed 
from the initial 100 µl and 50 µl of Fluo-4 DirectTM calcium reagent was added to each well. The 
plate was incubated at 37° C for 30 minutes at room temperature while protected from light. 
Controls included ionomycin (0.5 μM, Sigma ≥98% HPLC), ATP (0.5 μM, Sigma A1852), GABA 
(0.5 uM, Sigma BioXtra ≥99%) and LPS from E. coli (65 microgram/mL, Sigma L3755). The 
effect of treatments was assessed using a Nikon epifluorescence Ts2R scope at 10x magnification 
at 494 nm for excitation and 516 nm for emission for 60 seconds. The image intensity was 
calculated using ImageJ and is indicative of Ca2+ influx into the urothelial cell’s cytoplasmic space 
from either the extracellular environment or intracellular Ca2+ stores (here on out just referred to 
as Ca2+ influx). 
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2.5 Quantification of ATP 
A luminescent assay kit (BacTiter-Glo™ Microbial Cell Viability Assay, G8230) was used 
to quantify the amount of extracellular ATP released by the bacteria into the supernatant and 
released by the cells into the cell media. A microplate reader (Synergy™ H4 Hybrid Multi-Mode) 
was used to quantify the amount of extracellular ATP.   
 
2.6 Myofibroblast populated collagen contraction  
A collagen matrix was set up using 1.8 mg/ml sterile collagen and a neutralization 
solution156. The neutralization solution was made by mixing with three parts Waymouth Media 
(Sigma, W1625) and 2 parts 0.34M NaOH (Sigma, 221465). One-part neutralization mixture was 
then added to 4 parts collagen, mixed with 1x105 cells to a final volume of 500 µl and added to 
each well in a 24 well plate. After 45-minute incubation at 37⁰C, 1 mL 2% FBS was added to each 
well and the plate was incubated for an additional 72 hours at 37 ⁰C. The media was then removed, 
fresh media and treatment was added, and the collagen matrix was released using a sterile spatula. 
The plate was scanned using a scanner (Canon PIXMA MP250) immediately after release and also 
at 1, 3, 5 and 24 hours. The size of the collagen matrix was measured using ImageJ and the percent 
contraction was calculated. To decrease any shock to the myofibroblast, all bacterial strains were 
grown in DMEM with 2% FBS.  
 
2.7 Immunocytochemistry  
Myofibroblast cells were cultured in an 8 well µ-Slide (ibidi, 80826) to become fully 
confluent (90%-100%).  Cell cultures were washed with 1X PBS and fixed with 1 ml 4% 
paraformaldehyde per well for 10 minutes at room temperature, then 1 ml 0.1-0.2% Triton X-100 
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in PBS to each slide was added. After blocking the cells for non-specific staining with Background 
Sniper (Biocare Medical, BS966), they were incubated for 8 to 10 minutes, washed then incubated 
overnight at 4°C in 1% BSA in PBS containing Monoclonal Anti-Actin, α-Smooth Muscle (Sigma, 
A2547) diluted 1∶200. The cells were washed, excess liquid aspirated, and secondary antibody 
solution was added (1-10ug/ml) (Alexa Fluor 488 Donkey anti-mouse IgG secondary antibody, 
ThermoFisher, A-21202) in 1% BSA in PBS. The cells were protected from light and incubated 
for 45 minutes at room temperature. After washing with PBS, samples were incubated with 100 
μL DAPI (Diluted 1:10 000 in PBS) for 5 minutes in the dark. Confocal images were obtained 
with a Nikon Eclipse Ti2 (X60 objective lens, Nikon, Canada). Fluorescence intensity 
measurements were obtained from entire cells and analyzed with Image J software. Control 
specimens were identical to experimental specimens except they were exposed to irrelevant 
isotype matched antibody.  
 
2.8 Myofibroblast populated collagen RNA extraction and qPCR  
After incubation and aspiration of media, the collagen matrix was collected in 
microcentrifuge tubes for high-speed centrifugation for 5 minutes and then the supernatant was 
discarded. An aliquot of 100 μL pre-warmed 0.25 mg/ml collagenase was added to each well and 
incubated for 15 minutes at 37°C. RNA was isolated from the samples using the Direct-zol RNA 
Miniprep Kit (Zymo Research) following the manufacturer’s instructions, and Trizol reagent was 
used to lyse the samples. The RNA concentration was measured using nanodrop. cDNA was made 
following the instructions on the Applied Biosystems High Capacity cDNA Reverse Transcription 
Kit (Thermo-Fisher Scientific, MA) and PCR was conducted using a MasterCycler gradient PCR 
thermal cycler (Eppendorf, NY). Quantitative PCR was set up with each sample being run on the 
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plate in triplicate for each of the conditions, as described earlier. GAPDH was also used as the 
housekeeping gene. A list of the primers used can be found in Table 1.  
 
2.9 Statistical Analysis  
The data are expressed as mean ± SEM. Statistical significance was assessed using one-
way ANOVA followed by Tukey’s test (GraphPad Prism 5). Significance was determined when P 
< 0.05. 
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Chapter 3: RESULTS 
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3 Results  
3.1 Ca2+ influx of uroepithelial cell by bacterial supernatants  
All strains of bacteria for calcium assay were cultured in artificial urine. The supernatant 
of E. coli IA2 was able to induce the influx of Ca2+ into uroepithelial cells [Fig 2A]. Unlike a 
previous report103, LPS from E. coli did not stimulate the influx of calcium [Fig 2A]. Supernatants 
from E. coli IA2 and G. vaginalis ATCC 14018 increased the level of Ca2+ influx before plateauing 
at the 4-hour time point. In contrast, E. faecalis ATCC 33186 supernatants were not able to 
increase the level of Ca2+ influx until the 4-hour time point [Fig 2B, C and D].  
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Fig 2: Effects of E. coli IA2, G. vaginalis ATCC 14018 and E. faecalis ATCC 
33186 on the stimulation of Ca2+ influx in 5637 uroepithelial cells.  Supernatant 
from an overnight culture was added to the 5637 cells (A), supernatant from cultures of either E. 
coli IA2 (B) G. vaginalis ATCC 17018 (C), or E. faecalis ATCC 33186 (D) were taken hourly at 
1,2,3,4,5 and 24 hours post addition and tested for their ability to induce Ca2+ influx in the 5637 
cells. Forty μL of each treatment in artificial urine was added and fluorescence was measured using 
a Nikon epifluorescence Ts2R scope at 10x magnification at 494 nm for excitation and 516 nm for 
emission for 60 seconds. Image intensity was calculated using ImageJ. Each bar represents the 
total average image intensity 60 seconds after treatment of a duplicate sample. Statistical 
significance was determined using Tukey’s test, p≤0.05.  
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3.2 Lactobacillus crispatus ATCC 33820 and Lactobacillus gasseri ATCC KC-
1 supernatants reduce Ca2+ influx caused by uropathogenic bacteria  
All strains of bacteria for calcium assay were cultured in artificial urine. The addition of L. 
crispatus ATCC 33820 and L. gasseri KC-1 supernatants not only could not stimulate the influx 
of calcium like E. coli IA2, but also mitigated the effects of calcium influx caused by E. coli IA2 
supernatant by up to 50% [Fig 3A, B, C and D]. 
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Fig 3: Effect of L. crispatus ATCC 33820 and L. gasseri KC-1 supernatant on 
Ca2+ influx caused by uropathogenic supernatant. Treatments were added as either    
E. coli IA2 supernatant  and AU or L. crispatus ATCC 33820 supernatant and AU, or E. coli IA2 
supernatant+ L. crispatus ATCC 33820 supernatant (A), or E. coli IA2 supernatant and AU or          
L. gasseri KC-1 supernatant and AU, or E. coli IA2  supernatant+ L. gasseri KC-1 supernatant(B), 
or a six-fold serial dilutions of the L. crispatus ATCC 33820 supernatant in the E. coli IA2 
supernatant (C), image examples of calcium influx caused by E. coli IA2, L. crispatus ATCC 
33820 and a mixture of supernatants from the two bacteria (D). Fluorescence was measured using 
a Nikon epifluorescence Ts2R scope at 10x magnification at 494 nm for excitation and 516 nm for 
emission for 60 seconds. Image intensity was calculated using ImageJ. Each point represents the 
average image intensity of a time point done in duplicate. Statistical significance was determined 
using Tukey’s test, p≤0.05. 
 
 
 
 
 
 
 
 
 
 
32 
 
3.3 Quantification of bacterial extracellular ATP  
All strains of bacteria for ATP assay were cultured in artificial urine. In order to quantify 
the amount of extracellular ATP released in bacterial supernatants, a luminescent assay was used. 
Supernatants obtained from E. coli IA2, L. crispatus ATCC 33820 and L. gasseri KC-1 overnight 
cultures contained [0.098 ± 0.008 μM], [0.024 ± 0.003 μM] and [0.024 ± 0.001 μM ATP], 
respectively, which was higher than AU [0.0067 ± 0.0011 μM]. In addition, supernatants from 
organisms that comprise the urinary microbiota, including G. vaginalis ATCC 14018 and L. 
vaginalis NCFB 2810 contained [1.30 ± 0.14 μM] and [0.314 ± 0.023 μM] ATP, respectively, 
which was greater than the AU control of [0.0067 ± 0.0011 μM]. 
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Fig 4: Release of extracellular ATP by bacteria and cells. E. coli IA2, L. crispatus 
ATCC 33820, L. gasseri KC-1, G. vaginalis ATCC 14018 and L. vaginalis NCFB 2810 
supernatants were collected after overnight culture. The plate was incubated for 5 minutes and was 
read by a luminometer. A standard curve was generated using known concentrations of ATP to 
calculate the amount of ATP in each treatment sample. Each bar represents the average 
concentration of ATP in μM. Statistical significance was determined using Tukey’s test, p≤0.05. 
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3.4 ATP utilization by L. crispatus ATCC 33820 
The amount of ATP remaining when L. crispatus ATCC 33820 was grown in AU 
supplemented with 0.1 mM ATP for 24 hours was [21.67 ± 1.51 μM], less than half the control 
[51.56 ± 5.06 μM] (P≤0.0001) [Fig 5A]. To determine the main cause of ATP reduction, L. 
crispatus ATCC 33820 was cultured in AU supplemented with different concentrations of ATP, 
as well as in AU supplemented with 50% E. coli IA2 supernatant, and 25% G. vaginalis ATCC 
14018 supernatant individually as potential natural sources of ATP. The growth of L. crispatus 
ATCC 33820 was increased by increasing the ATP concentration, including ATP emanating from 
the E. coli IA2 and G. vaginalis ATCC 14018 supernatants [Fig 5B, C and D]. The L. crispatus 
ATCC 33820 also reduced the amount of ATP after overnight culture in AU supplemented with 
25% of E. coli IA2 supernatant, and 25% of G. vaginalis ATCC 14018 supernatant individually 
[Fig 5E and F]. Supplementing E. coli IA2 with ATP had a somewhat inhibitory effect on its 
growth [Fig 5G]. In the presence of ATP or supernatant from G. vaginalis ATCC 14018, the pH 
of L. crispatus, ATCC 33820 became further reduced [Fig 5H]. 
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Fig 5: ATP utilization by L. crispatus ATCC 33820. L. crispatus ATCC 33820 was 
grown in AU supplemented with 0.1 mM of ATP. After overnight culture, the amount of ATP was 
evaluated by a luminometer (A). Growth curves of overnight culture were performed by L. 
crispatus ATCC 33820 and E. coli IA2 in the presence of different concentrations of ATP in AU 
(B and G), as well as the growth curve of L. crispatus ATCC 33820 in AU supplemented by 50% 
of E. coli and 25% of G. vaginalis ATCC 14018 supernatants (C and D). The ability of L. crispatus 
ATCC 33820 to reduce the amount of ATP in AU supplemented with 25% of E. coli IA2 
supernatant, and 25% G. vaginalis ATCC 14018 supernatant individually, was also examined (E 
and F). The ability of 25% of G. vaginalis ATCC 14018 to induce L. crispatus ATCC 33820 to 
reduce pH was also examined (H). Each bar represents the average concentration of ATP in μM. 
Statistical significance was determined using Tukey’s test, p≤0.05. 
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3.5 The effect of sub-therapeutic concentrations of ciprofloxacin on the 
ability of E. coli IA2 to release ATP  
After culturing bacteria with different concentrations of ciprofloxacin from 10 μg/mL to 
0.031 μg/mL, the minimum inhibitory concentration (MIC) of the antibiotic against E. coli IA2 
was found to be between 1 to 1.5 μg/mL. [Fig 6A]. Using a concentration below the MIC, such as 
0.25, 0.125 or 0.0625 μg/mL caused E. coli IA2 to release more ATP up to 0.0247 ± 0.0015 μM 
[Fig 5B].   
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Fig 6: The effects of sub-therapeutic concentration of ciprofloxacin on E. coli 
IA2 to release ATP. Growth curves of an overnight culture of E. coli IA2 in the presence of 
different concentrations of ciprofloxacin in MRS were performed in order to determine the 
minimum inhibitory concentration of ciprofloxacin as well as subtherapeutic concentrations (A). 
E. coli IA2 supernatants were collected after overnight culture in MRS which supplemented with 
sub-therapeutic concentrations of ciprofloxacin. The plate was incubated for 5 minutes and was 
read by a luminometer (B). Each bar represents the average concentration of ATP in μM. Statistical 
significance was determined using Tukey’s test, p≤0.05. 
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3.6 Detection of ATP released by Urothelial cells 
The urothelial cell media contained 0.0042 μM ATP, and after treatment with 0.009 μM 
ATP for 2 minutes, the ATP released by the urothelial cells increased to 9.237 ± 0.172 μM [Fig 
7].  
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Fig 7: Urothelial cells release ATP. One hundred μl of RPMI was supplemented with 0.009 
μm ATP and incubated for two minutes to analyze the amount of ATP in the medium after 
incubation. One hundred μl media from 1x106 urothelial cell were also collected and incubated for 
two minutes to analyze the amount of ATP in the cell media. 1 x 106 urothelial cells were treated 
with 0.009 μM ATP and incubated for 2 minutes. Then, the whole cell medium (100 μl) that was 
treated with 0.009 μM ATP was removed to analyze the amount of ATP released by the urothelial 
cells after incubation. Each bar represents the average concentration of ATP in μM. Statistical 
significance was determined using Tukey’s test, p≤0.05. 
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3.7 Expression of MAOA and MAOB in the 5637 cells exposed to bacterial 
supernatants 
All strains of bacteria for the qPCR were cultured in RPMI 10% FBS. As ATP is capable 
of increasing the level of intracellular calcium, the influx of calcium can potentially cause 
mitochondrial dysfunction. Gene expression for mitochondrial enzymes, monoamine oxidase A 
and B was measured because of their potential ability to degrade neurotransmitters such as 
serotonin. The E. coli IA2 supernatant [ 0.78-fold change] caused downregulation in the level of 
MAOA gene expression, while L. crispatus ATCC 33820 supernatant [ 1.21-fold change] caused 
upregulation in the level of MAOA gene expression [Fig 8A]. The E. coli IA2 had no effect on 
MAOB gene expression, whereas, L. crispatus ATCC 33820 upregulated its expression by 44-fold 
[44.54-fold change] [Fig 8B]. 
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Fig 8: Fold change of transcript expression of monoamine oxidases. Supernatants 
from both pure cultures of E. coli IA2 and L. crispatus ATCC 33820 were added to 5637 cell 
cultures for 3 hours. Expression of the genes encoding monamine oxidases (MAOA/ MAOB) were 
measured by quantitative PCR relative to GAPDH as a house keeping gene expression (A and B). 
Statistical significance was determined using Tukey’s test, p≤0.05. N=2. 
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3.8 The effect of GABA and the GABA receptor on Ca2+ influx caused by 
ATP and bacterial supernatant 
The neurotransmitter γ-aminobutyric acid (GABA) was found to reduce the stimulation of 
calcium influx caused by ATP [Fig 9A] and inhibit the stimulation of calcium influx caused by E. 
coli IA2 supernatant [Fig 9B]. Inhibition of the GABA receptor by the GABA blocker reduced the 
ability of GABA to inhibit the stimulation of Ca2+ influx caused by ATP [Fig 9C].  
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Fig 9: Effect of GABA and GABA receptor on Ca2+ influx in 5637 cells caused 
by ATP and E. coli IA2. To evaluate the ability of GABA to inhibit the stimulation of Ca2+ 
influx caused by ATP, AU containing 0.5 μM GABA was mixed with 0.5 μM ATP in AU (A) 
Similarly, to test the ability of GABA to reduce the stimulation of calcium influx caused by 
bacterial supernatant, GABA was mixed with E. coli IA2 supernatant (B). In addition, to evaluate 
the ability of GABA blocker to reduce the ability of GABA to inhibit the stimulation of calcium 
caused by ATP, urothelial cells were treated with 100 uM GABA blocker for 1 minute and then a 
mixture of ATP and GABA was added (C). Fluorescence was measured using a Nikon 
epifluorescence Ts2R scope at 10x magnification at 494 nm for excitation and 516 nm for emission 
for 60 seconds. Image intensity was calculated using ImageJ. Each point represents the average 
image intensity of a time point done in duplicate. Statistical significance was determined using 
Tukey’s test, p≤0.05. 
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3.9 The role of GABA receptors in neutralizing ionic imbalances within the 
cell 
The GABA receptors facilitate the passing of anions such as chloride (Cl-) to interior of the cell, 
resulting in a decreased intracellular voltage and establishing an ionic balance. Blocking of the 
GABA receptors still allows the calcium channels to continue to function without restriction. It 
can be seen that the influx of calcium continues even after blocking the GABA receptor [Fig 10]. 
But, by blocking the purinergic and muscarinic receptors, the influx of Ca2+ has not changed. [Fig 
10].  
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Fig 10: The role of GABA receptor in the balance between anion and cation in 
the cell. To evaluate the role of GABA, purinergic and muscarinic receptors in the Ca2+ influx, 
the urothelial cells were treated with 100 μM GABA blocker, 5 μM purinergic blocker and 5 μM 
muscarinic blocker. Fluorescence was measured using a Nikon epifluorescence Ts2R scope at 10x 
magnification at 494 nm for excitation and 516 nm for emission for 60 seconds. Image intensity 
was calculated using ImageJ. Each point represents the average image intensity of a time point 
done in duplicate. Statistical significance was determined using Tukey’s test, p≤0.05. 
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3.10 The role of purinergic and muscarinic receptors to stimulate the influx of 
calcium  
The stimulation of calcium influx caused by ATP after blocking the purinergic receptors decreased 
as expected [Fig 11 A]. However, while the calcium influx was reduced, it did not stop [Fig 11 A]. 
Ca2+ influx caused by ATP after blocking of muscarinic receptor was not diminished, indicating 
that the muscarinic receptor has no role in calcium transfer [Fig 11 B].   
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Fig 11: The role of purinergic or muscarinic receptors on the influx of calcium. 
To evaluate the role of purinergic, muscarinic receptor to stimulate the influx of calcium, the 
urothelial cells were treated with: 5 μM purinergic blocker for one minute, and then 40 μM ATP 
was added (A) and also 5 μM muscarinic blocker for one minute, and then 40 μM ATP was added 
(B). Fluorescence was measured using a Nikon epifluorescence Ts2R scope at 10x magnification 
at 494 nm for excitation and 516 nm for emission for 60 seconds. Image intensity was calculated 
using ImageJ. Each point represents the average image intensity of a time point done in duplicate. 
Statistical significance was determined using Tukey’s test, p≤0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
3.11 Myofibroblast contraction assay  
All strains of bacteria for the collagen contraction assay were cultured in DMEM 2% FBS. 
The collagen contraction assay using primary myofibroblast cells seeded on top of a collagen 
matrix was tested against bacterial products. Supernatants from cultures of E. coli IA2 were able 
to induce the greatest degree of contraction [72.67% ± 0.87] in the myofibroblast cell line after 24 
hours, and this was reduced when L. crispatus ATCC 33820 or L. gasseri KC-1 supernatants were 
added [48.56% ± 1.68, 29.82% ± 0.023, respectively] [Fig 12A, B and C]. Purified ATP caused 
the contraction of myofibroblasts in the first hour [30.30% ± 3.25] and continued for 24 hours 
[60.73 % ± 1.49] [Fig 12A and D]. While, GABA did not cause contraction in the myofibroblast 
assay, it inhibited contraction caused by E. coli IA2 [Fig 12A and E].  
Previous reports13 suggest that the contraction caused by E. coli IA2 was due to LPS. 
However, after five hours of exposure of LPS to the myofibroblasts, contraction was half that 
induced by ATP [27.26% ± 1.05 versus 46.19 ± 1.78%] [Fig 12A and F].  
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Fig 12: Contraction of myofibroblast populated collagen matrix by bacterial 
supernatant, neurotransmitters and LPS. Bacterial supernatants from E. coli IA2, L. 
crispatus ATCC 33820 and L. gasseri KC-1 were added to a myofibroblast populated collagen 
matrix.  In addition, GABA, ATP and LPS were included as controls (B-F). The final volume in 
each well was 500 uL and the collagen matrix was scanned at T= 1,3,5 and 24h and % contraction 
was determined using ImageJ. Each point represents the average % contraction of a duplicate 
sample.  
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3.12 Immunocytochemistry for intracellular alpha smooth muscle actin (α-
SMA)  
To further confirm that bacterial compounds impact myofibroblast contractive abilities, the 
effect on alpha smooth muscle actin was assessed. The E. coli IA2 supernatant did not increase the 
expression of the ACTA2 [ 0.9798759-fold change] [Fig 13C]. L. crispatus ATCC 33820 also 
downregulated the level of ACTA2 gene expression [0.5946411-fold change] [Fig 13C]. Thus, the 
ability of E. coli IA2 to increase the intracellular image intensity [Fig 13A and B] could potentially 
be based on alpha smooth muscle cells contraction, and the ability of L. crispatus ATCC 33820 to 
reduce the intracellular image intensity [Fig 13A and B] could potentially be based on alpha 
smooth muscle cells relaxation. 
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Fig 13: Confocal fluorescence microscopy analysis. Bacterial supernatants from E. coli 
IA2, L. crispatus ATCC 33820 and in combination were co-cultured with myofibroblasts for 1 
hour (A and B). The image intensity was measured by confocal microscopy with DAPI and FITC 
to show staining of alpha-smooth muscle actin. Bacteria supernatants identical to A, were added 
to the myofibroblasts that were grown in the collagen matrix and then incubated at 37°C with 5% 
CO2 for 3 hours and tested for gene expression of alpha-smooth muscle actin (ACTA2) (C). Image 
intensity was calculated using ImageJ. Each point represents the average image intensity of three 
cells. Statistical significance was determined using Tukey’s test, p≤0.05. Expression of the gene 
encoding ACTA2 was measured by quantitative PCR relative to beta-actin as a house keeping gene 
expression. Statistical significance was determined using Tukey’s test, p≤0.05. N=2.  
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3.13 Evaluation of the bacterial supernatants to alter the tumor necrosis 
factor (TNF) gene expression in the myofibroblast assay  
All strains of bacteria for the qPCR were cultured in DMEM 2% FBS. To determine if sustained 
activation of the calcium channel promoted apoptosis by bacterial components, TNF was measured 
as an indicator. the E. coli IA2 caused more than 700-fold upregulation [714 ± 19.91] of TNF [Fig 
13], whereas, exposure to L. crispatus ATCC 33820 only resulted in three-fold increase [3.9 
±0.115]. When E. coli IA2 and L. crispatus ATCC 33820 supernatants were mixed and applied to 
the assay, the expression of TNF induced by the E. coli IA2 was strongly mitigated [52.38 ± 3.98] 
[Fig 13]. 
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Fig 14: Lactobacillus crispatus ATCC 33820 can mitigate the expression of TNF 
caused by E. coli IA2. Bacterial supernatants, identical to the recipe of Fig 12, were added to 
the myofibroblasts that were grown in the collagen matrix and then incubated at 37 ° C with 5% 
CO2 for 3 hours.  Expression of the gene encoding TNF was measured by quantitative PCR relative 
to beta-Actin as a house keeping gene expression. Statistical significance was determined using 
Tukey’s test, p≤0.05. N=2.     
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4 Discussion  
This study has shown that bacteria known to be present in the urinary microbiota may have 
the potential to influence bladder contractility. Evidence was acquired from uroepithelial and 
myofibroblast cell models. Uropathogenic bacteria by releasing extracellular excitatory 
compounds such as ATP induces Ca2+ influx. This along with release of ATP could potentially 
stimulate bladder contraction.  
Prior to testing bacterial supernatants, the 5637 uroepithelial cells were shown to be 
capable of responding to agonists known to induce Ca2+ influx. Ionomycin, as well as ATP, were 
all able to induce Ca2+ influx as previously described in the literature 104,105. Unsurprisingly, GABA 
as an inhibitory neurotransmitter was unable to stimulate Ca2+ influx106.   
To evaluate the ability of bacteria to induce Ca2+ influx, it is important to use a cell culture 
medium in which all bacterial strains can grow well but cannot stimulate the influx of calcium. 
Interestingly, artificial urine did not stimulate calcium influx, and all strains of bacteria used in 
this study grew in this medium.   
In a healthy person consuming regular fluids, the bladder empties urine at regular intervals. 
The period between voiding is shortened and uncontrolled in UUI patients. Thus, for 
uropathogenic bacteria to have a role, they must release compounds in the timeframe between 
voiding.  
Supernatants from E. coli IA2, G. vaginalis ATCC 14018, and E. faecalis ATCC 33186 
cultures caused Ca2+ influx after 24 hours, but only E. coli IA2 and G. vaginalis ATCC 14018 
consistently increased this influx and did so at the beginning of their log growth phase. The failure 
of E. faecalis ATCC 33186 to cause the influx of calcium within the timeframe between voidings 
in UUI patients suggests it may play less of a role in this disease. This correlates with E. faecalis 
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ATCC 33186 being associated more with ABU than symptomatic UTI107,108. Since ABU-causing 
bacteria have longer doubling times and weaker adherence109-112, the act of involuntary voiding 
thus prevents them from having sufficient time to produce agonists for receptors or channels 
responsible for Ca2+ transport.  
Nevertheless, E. faecalis ATCC 33186 and E. coli IA2 released ATP into their extracellular 
environment, as noted by others113, 114. This may be one of the potential agonists for causing Ca2+ 
influx in the cells as demonstrated with in Figure 8A.  
The results pertaining to G. vaginalis ATCC 14018 were of interest because this organism 
is known to be associated with BV, and patients with this condition often report the urge to void 
urine. This species can ascend to the bladder through the urethra115, 116, and forms part of the 
urinary microbiota. Its high capacity to release ATP (1.30 ± 0.14 μM), may be sufficient for 
uroepithelial cells to release more ATP in the sub-urethral space, but in context of mitochondrial 
dysfunction could potentially be responsible for cellular apoptosis. 
In contrast, L. crispatus ATCC 33820 and L. gasseri KC-1 were unable to release ATP to 
the same extent as E. coli IA2, and interestingly both reduced the influx of Ca2+ caused by E. coli 
IA2. In addition, serial dilution experiments indicate that small amounts of L. crispatus ATCC 
33820 compounds could cause this effect. 
The attributes of L. crispatus ATCC 33820 and L. gasseri KC-1 are not associated with all 
lactobacilli. For example, L. vaginalis NCFB 2810 is commonly found in the oral, vaginal and 
intestinal regions117 and it has been shown to release 0.314 ± 0.023 μM ATP, which is three times 
more than E. coli IA2, and L. crispatus ATCC 33820 and L. gasseri KC-1 (0.024 ± 0.003 μM and 
0.024 ± 0.001 μM ATP respectively) are significantly less than L. vaginalis NCFB 2810.  
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Although the actual mechanism for a decrease in Ca2+ influx is unknown, it might be that 
L. crispatus ATCC 33820 and L. gasseri KC-1 release inhibitory neurotransmitters or antagonist 
compounds. One possible compound is GABA, with several Lactobacillus able to produce it using 
glutamate decarboxylase118 Three mechanisms are proposed to explain the lactobacilli countering 
E. coli-induced bladder contractility.  
The first is based on the ability of the GABA receptor, glycine receptor and VRAC to 
control chloride influx. Many receptors like purinergic and TRP are expressed in urothelial cell, 
sub-urethral tissue and smooth muscle cells, and are sensitive to ATP and stimulation may cause 
calcium influx. By increasing the level of intracellular calcium, the intracellular voltage is 
increased and leads the cell to a depolarization phase, essential for cell function. This drives the 
cell to release ATP into the sub-urethral space and change bladder contractility. However, 
increasing the level of intracellular calcium can regulate many important mechanisms in the cell, 
though continuous activation of calcium channels leading to urothelial apoptosis. Therefore, 
urothelial cells need the inhibitory mechanisms to protect against abnormally high calcium levels. 
These mechanisms could potentially be based on the function of chloride channels. Many receptors 
like GABA, glycine and VRAC have the function of chloride channel. The stimulation of these 
receptors by chloride influx can decrease intracellular voltage and provide an equilibrium between 
intracellular cation and anion levels, leading to an inhibitory hyperpolarization phase [Figure 15]. 
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Fig 15: How ATP released from uropathogenic bacteria induces urothelial cells 
to release more ATP into the sub-urethral. In UTI, ATP released by E. coli binds to TRP 
channels and purinergic receptors and causes calcium influx (1). Increasing the level of 
intracellular calcium is forced urothelial cells into ATP exocytosis. Some part of ATP in the sub-
urethral binds to the receptors of the afferent sympathetic pelvic nerve and sends signals to the 
brain (2). On the other hand, the brain sends signals to the bladder through the parasympathetic 
efferent pelvic nerve releases Ach and ATP into the sub-urethral space. These excitatory 
neurotransmitters bind to corresponding receptors of smooth muscle cells and cause contraction 
(3). The other part of ATP can directly stimulate the corresponding receptors on smooth muscle 
cells and cause contraction. But, in the normal bladder, commensal GABA-releasing bacteria 
stimulate chloride channels that, by reducing intracellular voltage, drive urothelial cells into a 
hyperpolarization phase and regulate bladder contractility (4). 
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The experiments showed that GABA can reduce ATP-mediated calcium stimulation. But, 
when the GABA receptor is blocked by GABA receptor antagonist, it cannot reduce the influx of 
Ca2+ caused by ATP. This shows the importance of the GABA receptor in balancing anion and 
cation levels within the cells through chloride import. When the GABA receptor is blocked, one 
of the chloride channels is disrupted and the Ca2+ channels continue to import with lower inhibitory 
pressure. Notably, when urothelial cells were treated with purinergic and muscarinic blockers, 
there was no apparent stimulation of Ca2+ influx.  
Another interesting result obtained pertaining to purinergic and muscarinic receptors 
demonstrated that they can import calcium. Due to the role of purinergic receptors in the Ca2+ 
pathway, the stimulation of calcium influx caused by ATP decreased following treatment with a 
purinergic. These results indicate that the muscarinic receptor has no role in passing Ca2+ from 
outside to inside urothelial cells.  
One of the downstream effects of Ca2+ influx in cells is ATP release into the extracellular 
environment, including the sub-urethral space120. In the urothelium, extracellular ATP serves as a 
key signaling molecule to tell the brain that the bladder is becoming full, which may lead to 
contraction of the detrusor bladder muscles120,121. 
As mentioned previously, the bladder uroepithelium is a barrier which acts as a sensor to 
inhibit the voiding reflux. Under certain conditions, it can release ATP via the connexin 
hemichannels, pannexin and several anion channels122. The vesicular nucleotide transporter 
(VNUT) which can be expressed in uroepithelial cells is responsible for the ATP exocytosis. It is 
possible that stimulation of calcium influx in urothelial cells may cause increased expression of 
VNUT, with release of ATP into the sub-urethral space thereby affecting bladder contractility. 
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The second mechanism to consider is the role of L. crispatus ATCC 33820 releasing 
compounds that act as calcium channel antagonists by binding to the receptor site and blocking 
ATP binding. One such compound could be GABA. After blocking the GABA receptor, the ability 
of GABA to inhibit ATP-mediated calcium stimulation was diminished, but not eradicated. Even 
with GABA not bound to its receptor, it still reduced the stimulation of calcium caused by ATP, 
perhaps by acting as an antagonistic compound or calcium channel blocker.  
The third mechanism is the ability of L. crispatus ATCC 33820 to utilize the excess ATP 
released by urogenital pathogens during UTI. This result indicates there is a possibility that L. 
crispatus ATCC 33820 can degrade the excess ATP. To investigate this, L. crispatus ATCC 33820 
was cultured in artificial urine supplemented with various concentrations of ATP, as well as 50% 
of E. coli IA2, and 25% G. vaginalis ATCC 14018 supernatants. The results show that ATP and 
the pathogenic supernatants induce L. crispatus ATCC 33820 to grow further, and after overnight 
culture, L. crispatus ATCC 33820 reduced the amount of ATP in the bacterial supernatants.    
In contrast, the culture of E. coli IA2 with different concentrations of ATP functioned as 
an inhibitory compound to reduce bacterial growth. In the presence of ATP or supernatant from 
G. vaginalis ATCC 14018, the pH of L. crispatus ATCC 33820 dropped even further. It appears 
that ATP increases L. crispatus ATCC 33820 metabolism, resulting in additional growth and 
subsequently increased lactic acid production. 
In patients with UTI, antibiotics reduce the number of bacteria in the lumen, but those 
embedded in the uroepithelial cells or tissues, may resist the sub-therapeutic concentrations that 
reach them123. It is feasible that the subtherapeutic concentration of antibiotics could induce 
bacteria to release more ATP124, thereby worsening neurological feedback and increasing bladder 
contractions. Using sub-therapeutic concentrations of ciprofloxacin for E. coli IA2 (0.25, 0.125 
80 
 
and 0.0625 μg/mL), more ATP was released into the media. Sub-therapeutic concentrations of 
ciprofloxacin can potentially stimulate hydrogen channels and cause hydrogen influx. By passing 
the H+ of the hydrogen channel, sufficient energy is generated for the production of ATP from 
adenosine diphosphate (ADP). By increasing the level of ATP in the bacterial cell, ATP can be 
released through efflux pumps125. 
Experiments showed that E. coli IA2 supernatant can affect MAOA and MAOB gene 
expression that can degrade biogenic amine neuroactive chemicals. Reducing the level of these 
enzymes can worsen the neurological disorders. The downregulation of MAOA expression, 
potentially based on the bacterial ATP release, increases the intracellular calcium causing 
enzymatic dysfunction of the mitochondria29. In contrast, L. crispatus ATCC 33820 upregulated 
MAOA/B expression, possibly based on the ability of these bacteria to release inhibitory 
compounds to establish an equilibrium between anions and cations, resulting in normal 
mitochondrial. Monoamine oxidase enzymes, MAOA and MAOB are found on the outer 
membrane of the mitochondria in eukaryotic cells and are critical for the breakdown of biogenic 
amine neuroactive chemicals such as tyramine, serotonin and dopamine. Decreased MAO enzyme 
activity has been linked to neurological disorder126.  
Continuous activation of calcium channels and related receptors may result in abnormally 
high levels of calcium influx and lead the cell to its apoptotic phase. Apoptotic cells first undergo 
surface blebbing, then break into many membrane-bound apoptotic bodies121. Increased 
intracellular calcium can cause calcium overload in the mitochondria, leading to mitochondrial 
dysfunction. Under certain conditions, the mitochondrial permeability transition (MPT), a protein 
that forms in the inner membrane, allows the mitochondria to pass molecules smaller than 1500 
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daltons. Since ATP has a molecular weight of 551.2 daltons, it can cross the mitochondrial 
membrane into the cytosol, causing a depletion in mitochondrial ATP127.  
Serotonin, a substrate of these MAO enzymes, has been shown to induce contraction of the 
human detrusor muscle. Therefore, if serotonin is not being degraded as efficiently, it could 
stimulate the cholinergic neurons that innervate the detrusor and cause contraction128. 
Lactobacillus crispatus ATCC 33820 increased production of MAO enzymes and, by breaking 
down certain neurotransmitters, could potentially reduce bladder contractility.  
Fibroblasts play key roles during growth and healing after injury. They invade the wound 
and create a mature wound matrix. During the granulation phase, fibroblasts begin to obtain a new 
phenotype with an important contractile structure, expressing contractile proteins like alpha-SMA 
which are typical of SMA, particularly vascular smooth muscle cells129. This provides support for 
use of myofibroblasts to examine contractility.  
In fibroblasts, TNF induces apoptosis with the binding to TNF receptor-1 activating 
proteins associated with this receptor, leading to activation of the apoptotic cascade130-132. Since 
bacterial compounds can pass through compromised uroepithelium and cross the sub-urethral 
space to reach smooth muscle cells, investigating the effects of bacterial compounds on TNF 
expression is important. The protective role of L. crispatus ATCC 33820 in reducing the 
expression of TNF induced by E. coli IA2 is worth pursuing, as is the ability of L. crispatus ATCC 
33820 to release a calcium channel blocker. 
An interesting finding with the collagen gel contraction assay is the ability of L. crispatus 
ATCC 33820 and L. gasseri KC-1 to not only cause contraction in myofibroblasts, but also to 
inhibit the contraction caused by compounds released by E. coli IA2. While the mechanism is 
unknown, it is proposed to involve the release of neuroactive molecules by the bacteria— ATP, 
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Ach as well as other stimulatory neurotransmitter in the case of uropathogens, and inhibitory 
neurotransmitters such as GABA and glycine in the case of L. crispatus ATCC 33820 and L. 
gasseri KC-1.  
An important question that should be answered is: what is the main reason for 
myofibroblast contraction? The contraction of the collagen matrix has two main explanations, 
myofibroblast contraction and myofibroblast motion. By releasing an excitatory compound like 
ATP, E. coli IA2 can stimulate receptors like purinergic and TRP as calcium channels and cause 
the influx of calcium. By increasing the amount of intracellular calcium through the mechanism 
below, contraction of myofibroblasts and smooth muscle cells can be induced.  
Actin and myosin interact according to sliding filament theory. The final trigger for 
contractions is a rise in intracellular Ca2+, which interacts with calmodulin and myosin light chain 
kinase to activate myosin. Calcium binds to calmodulin, activates it, then activates the kinase 
enzyme causing transfer of a phosphate group from ATP to myosin cross-bridges. Phosphorylated 
cross-bridges interact with actin to produce shortening, and therefore cellular contraction133.  
Alpha-SMA in addition to being a marker of myofibroblast differentiation has been 
suggested to play a role in the production of contractile force during wound healing and fibro-
constrictive diseases134. Here, a direct correlation was found between the contraction of α-SMA 
and the contraction of collagen gel caused by urogenital pathogens. There was also a direct 
correlation between α-SMA relaxation and relaxation of the collagen caused by L. crispatus ATCC 
33820. Confocal microscopy showed that E. coli IA2 caused an increase in intracellular light 
intensity related to α-SMA. This has two possible explanations, an increase in the amount of 
intracellular α-SMA or the contraction of α-SMA.  Studies using qPCR showed that E. coli IA2 
compounds had no effect on ACTA2 gene expression, suggesting that the image intensity could be 
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related to α-SMA contraction. On the other hand, since L. crispatus ATCC 33820 caused 
downregulation on ACTA2 expression, the ability of L. crispatus ATCC 33820 to reduce the α-
SMA image intensity could be based on the ability of L. crispatus ATCC 33820 to downregulate 
ACTA2 gene expression. 
 
Conclusion 
These studies report the ability of urogenital pathogens to stimulate pathways associated 
with unintentional bladder contraction and UUI in an in vitro model, and the ability of indigenous 
members of the urinary microbiota, L. crispatus ATCC 33820 and L. gasseri KC-1, to mitigate the 
effects. These findings have implications for the approach to how UUI patients are managed, and 
potentially for the design of interventions that propagate lactobacilli in the bladder.  
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Table 1: Primers  
Primer Primer Pair 
ID 
Gene Name Gene 
Symbol 
Gene 
ID 
Exons 
GAPDH 
Sigma 1235 
H_GAPDH_1 Glyceraldehyde-
3-phosphate 
dehydrogenase 
GAPDH 2597 9-10 
MAOA 
Sigma 1257 
H_MAOA_1 Monoamine 
oxidase A 
MAOA 4128 3-5 
MAOB 
Sigma 1257 
H_MAOB_1 Monoamine 
oxidase B 
MAOB 4129 12-13 
TNF 
ThermoFisher 
Scientific  
Hs00174128_m1  
H-TNF-alpha Tumor necrosis 
factor 
TNF-α 7124 3-4 
ACTA2 
ThermoFisher 
Scientific  
 Hs00426835_g1 
H-ACTA2 Actin, alpha 2, 
smooth muscle, 
aorta 
ACTA2 11475 2-3 
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Abbreviations:  
UUI  Urgency Urinary Incontinence 
OAB  Overactive Bladder Syndrome  
UTIs  Urinary Tract Infections  
ABU  Asymptomatic bacteriuria  
ATP  Adenosine triphosphate  
SMC  Smooth Muscle Cell  
α-SMA Alpha-Smooth Muscle actin 
ADP  Adenosine diphosphate 
GABA  Gamma Aminobutyric Acid  
Ach  Acetylcholine  
NO  Nitric Oxide  
TRP  Transient receptor potential  
P  Purinergic  
NMDA N-methyl-D-aspartate  
MAO  Monoamine Oxidase  
GRIN1 Glutamate Ionotropic Receptor NMDA type subunit 1  
VRACs Volume-Regulated Anion Channels  
GAD  Glutamate Decarboxylases  
Cl-  Chloride  
Ca2+   Calcium  
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